NCT00745329

Brief Summary

Background: The treatment of inflammatory bowel diseases (IBD) is based mainly on 3 compounds: 1- 5 aminosalysilates . 2- immunomodulators (Azathioprines). 3- Biologic therapies (Infliximab, Adalimumab) . There are no established data in the literature whether these therapies effects sperm quality. Given that a large number of the patients are young men in the reproductive stage of their lives , It of importance to investigate these effect. Aim: To investigate the effect of chronic treatment of any of the three therapy mentioned above, on sperm quality .

Trial Health

50
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 1, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 3, 2008

Completed
28 days until next milestone

Study Start

First participant enrolled

October 1, 2008

Completed
Last Updated

September 3, 2008

Status Verified

September 1, 2008

First QC Date

September 1, 2008

Last Update Submit

September 2, 2008

Conditions

Study Arms (1)

2

1. patients 2. healthy volunteers

Other: sperm quality test

Interventions

All participants will undergo sequential sperm quality tests and blood tests

2

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with inflammatory bowel disease (IBD) and healthy volunteers

You may qualify if:

  • Male above the age of 18
  • Capable of giving informed consent
  • Diagnosed with IBD at least 3 months
  • Patients that are going to start a treatment with on of the following groups: 5ASA, Azathioprines, infliximab or ADAlimumab
  • Patients that are treated with therapies mentioned in article 4 for at least 3 months

You may not qualify if:

  • Male younger than 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Crohn DiseaseColitis, Ulcerative

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal DiseasesColitisColonic Diseases

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

September 1, 2008

First Posted

September 3, 2008

Study Start

October 1, 2008

Last Updated

September 3, 2008

Record last verified: 2008-09